COVID-19 vaccine trials should seek worthwhile efficacy

"The criteria used to define a successful vaccine in the initial clinical trials of vaccination versus placebo should be strict enough to protect against the risk of a weakly effective vaccine being deployed, especially since there are already many candidate vaccines against COVID-19 to be tested, providing many chances to overestimate efficacy.WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%". The Lancet

Other news